Trials / Not Yet Recruiting
Not Yet RecruitingNCT07536789
Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma: A Single-arm, Multi-cohort, Phase 2 Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of Becotatug vedotin, MRG003, in previously treated advanced hepatocellular carcinoma (HCC).
Detailed description
Two cohorts will be recruited. Cohort 1 will recruit advanced HCC with EGFR expression 3+. Cohort 2 will recruit advanced HCC with EGFR expression 0-2+. Both cohorts will receive MRG003 monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRG003 | MRG003 will be administered by IV, 2.3 mg/kg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. |
Timeline
- Start date
- 2026-04-15
- Primary completion
- 2028-04-15
- Completion
- 2029-04-14
- First posted
- 2026-04-17
- Last updated
- 2026-04-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07536789. Inclusion in this directory is not an endorsement.